Clinicopathological features, psychological status, and prognosis of 33 patients with occult breast cancer

Table 1 Clinicopathological features and 5-year disease-free survival rate of occult breast cancer patients

Clinical features	n	5-year DFS rate (%)	χ2	P value
Whole patient cohorts	33	55.7
Age (yr)			0.20	0.887
< 50	9	58.9
≥ 50	24	55.8
BMI			0.294	0.588
< 23.9	24	51.7
≥ 23.9	9	87.5
Menopause			2.923	0.087
Yes	23	46.9
No	10	80.0
N staging			5.448	0.020a
1	15	92.3
≥ 2	18	34.3
Initial tumor site			5.333	0.021a
Armpit	30	60.8
Neck	3	-
M staging			1.486	0.223
0	24	46.2
1	9	53.3
Ki67			0.317	0.573
≤ 14%	8	60.0
> 14%	25	54.1
ER			0.003	0.953
Positive	18	55.1
Negative	15	56.0
PR			2.355	0.125
Positive	17	67.1
Negative	16	34.8
Her-2			0.111	0.739
Positive	18	66.4
Negative	15	42.2
Molecular subtyping			1.690	0.639
Luminal A	15	73.4
Luminal B	12	27.8
Her-2 enriched	3	50.0
TNBC	3	-

^aP < 0.05 between the groups.

OBC: Occult breast cancer; BMI: Body mass index; DFS: Disease free survival; ER: Estrogen receptor; PR: Progesterone receptor.

Table 2 Patients’ depression and anxiety scores

Categories	Minimum	Maximum	Score
SDS	44	64	56.40 ± 4.29
SAS	48	69	60.77 ± 4.58

SDS: Self-rating depression scale; SAS: Self-rating anxiety scale.

Table 3 Patients’ emotions, stress perception and psychological resilience

Categories	Minimum	Maximum	Score
Positive and negative affect schedule
Positive	10	32	18.23 ± 4.38
Negative	22	39	27.97 ± 4.37
Chinese Perceived Stress Scale	32	48	42.13 ± 3.12
Connor-Davidson Resilience Scale	38	56	47.53 ± 4.03

Table 4 Univariate and multivariate analysis of prognosis

Treatment method	n	5-year DFS rate (%)	χ2	P value
Total	33
Surgery			1.486	0.223
With	24	46.2
Without	9	53.1
Radiotherapy			10.450	< 0.001
With	16	88.9
Without	17	21.4

DFS: Disease-free survival.

Table 5 Five-year disease-free survival rate of patients

Surgical modalities used for patients	n	5-year DFS rate (%)	χ2	P value
Total	24
Surgical method			0.751	0.687
Modified radical mastectomy	18	35.7
Axillary lymph node dissection	5	50.0
Breast-conserving surgery + axillary lymph node dissection	1	-
Neoadjuvant therapy			0.168	0.682
With	12	0.571
Without	12	0.458

DFS: Disease free survival.

Table 6 Effects of treatment modalities on disease free survival

Endocrine therapy for hormone receptor-positive patients	n	5-year DFS rate (%)	χ2	P value
Total	20
Drugs used for endocrine therapy			1.669	0.434
Tamoxifen	10	0.370
Goserelin	6	1.000
Anastrozole/letrozole	4	0.667

DFS: Disease free survival.